BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Adult Hodgkin lymphoma AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7 AND Treatment
759 results:

  • 1. Efficacy and Nuances of Precision Molecular Engineering for hodgkin's Disease to a Gene Therapeutic Approach.
    Qadir MI; Ahmed B; Hussain N
    Crit Rev Immunol; 2024; 44(5):41-50. PubMed ID: 38618727
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
    Polgarova K; Trneny M
    Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-hodgkin lymphoma patients treated with R-CHOP.
    Dhar S; Chakravarti M; Ganguly N; Saha A; Dasgupta S; Bera S; Sarkar A; Roy K; Das J; Bhuniya A; Ghosh S; Sarkar M; Hajra S; Banerjee S; Pal C; Saha B; Mukherjee KK; Baral R; Bose A
    Front Immunol; 2023; 14():1303959. PubMed ID: 38304256
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell lymphoma: Real-World Data Analysis.
    Ip A; Mutebi A; Wang T; Jun M; Kalsekar A; Navarro FR; Wang A; Kamalakar R; Sacchi M; Elliott B
    Adv Ther; 2024 Mar; 41(3):1226-1244. PubMed ID: 38302846
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Bispecific antibodies in indolent B-cell lymphomas.
    Radhakrishnan VS; Davies AJ
    Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Consensus recommendations on the management of toxicity associated with CD3×cd20 bispecific antibody therapy.
    Crombie JL; Graff T; Falchi L; Karimi YH; Bannerji R; Nastoupil L; Thieblemont C; Ursu R; Bartlett N; Nachar V; Weiss J; Osterson J; Patel K; Brody J; Abramson JS; Lunning M; Shah NN; Ayed A; Kamdar M; Parsons B; Caimi P; Flinn I; Herrera A; Sharman J; McKenna M; Armand P; Kahl B; Smith S; Zelenetz A; Budde LE; Hutchings M; Phillips T; Dickinson M
    Blood; 2024 Apr; 143(16):1565-1575. PubMed ID: 38252906
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Clinical and pathological characteristics and prognosis analysis of gray zone lymphoma].
    Liu SZ; Zong XP; Cai WZ; He HJ; Ma ZX; Li JQ; Li CX; Wu DP
    Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(1):69-73. PubMed ID: 38178771
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly
    Takaura K; Ando H; Ganoza ER
    Nihon Yakurigaku Zasshi; 2024; 159(1):61-68. PubMed ID: 38171842
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
    Cabrero M; López-Corral L; Jarque I; de la Cruz-Vicente F; Pérez-López E; Valcárcel D; Sanz J; Espigado I; Ortí G; Martín-Calvo C; de la Serna J; Caballero D;
    Bone Marrow Transplant; 2024 Mar; 59(3):359-365. PubMed ID: 38167647
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R cd20-negative transformed follicular lymphoma with
    Zhang J; Cai D; Gao R; Miao Y; Cui Y; Liu Z; Zhang H; Yan X; Su N
    Front Immunol; 2023; 14():1307242. PubMed ID: 38143763
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Loss of cd20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
    Schuster SJ; Huw LY; Bolen CR; Maximov V; Polson AG; Hatzi K; Lasater EA; Assouline SE; Bartlett NL; Budde LE; Matasar MJ; Koeppen H; Piccione EC; Wilson D; Wei MC; Yin S; Penuel E
    Blood; 2024 Feb; 143(9):822-832. PubMed ID: 38048694
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Rare primary pulmonary mucosa-associated lymphoid tissue lymphoma misdiagnosed with tuberculosis: A case report.
    Gu M; Ji D; Lu Y; Ping G; Yan C
    Medicine (Baltimore); 2023 Nov; 102(46):e36125. PubMed ID: 37986314
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study.
    Allouchery M; Brunet K; Tomowiak C; Singier A; Pambrun E; Pariente A; Bezin J; Pérault-Pochat MC; Salvo F
    Mycoses; 2024 Jan; 67(1):e13676. PubMed ID: 37984556
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-hodgkin lymphoma.
    Ikoma Y; Nakamura N; Kitagawa J; Miwa T; Takada E; Matsumoto T; Shibata Y; Nakamura H; Kanemura N; Kasahara S; Hara T; Sawada M; Tsurumi H; Shimizu M
    Hematol Oncol; 2024 Jan; 42(1):e3236. PubMed ID: 37932900
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
    Izutsu K; Kumode T; Yuda J; Nagai H; Mishima Y; Suehiro Y; Yamamoto K; Fujisaki T; Ishitsuka K; Ishizawa K; Ikezoe T; Nishikori M; Akahane D; Fujita J; Dinh M; Soong D; Noguchi H; Buchbjerg JK; Favaro E; Fukuhara N
    Cancer Sci; 2023 Dec; 114(12):4643-4653. PubMed ID: 37921363
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory cd20
    Munoz J; Flinn IW; Cohen JB; Sachs J; Exter B; Ranger A; Harris P; Payumo F; Nath R; Hamadani M; Westin JR; Bachanova V
    Transplant Cell Ther; 2024 Feb; 30(2):241.e1-241.e8. PubMed ID: 37898374
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma.
    Yang X; Luo C; Qian J; Huang X; Zhang J; Wang J; Luo C; Qin X; Li B; Chen J
    Front Immunol; 2023; 14():1219872. PubMed ID: 37736096
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. lymphomas of Central Nervous System.
    Yokogami K; Azuma M; Takeshima H; Hirai T
    Adv Exp Med Biol; 2023; 1405():527-543. PubMed ID: 37452952
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [Gray zone lymphoma: five cases report and literature review].
    Zou HS; Zhang HJ; Liu HM; Huang WY; Liu W; Lyu R; Wang TY; Sui WW; Fu MW; Wang Q; Qiu LG; Zou DH
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):242-246. PubMed ID: 37356987
    [No Abstract]    [Full Text] [Related]  

  • 20. Nodular lymphocyte-predominant hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment.
    Eichenauer DA; Hartmann S
    Expert Rev Hematol; 2023; 16(8):607-615. PubMed ID: 37337881
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 38.